• Steris entered a $1.6 billion revolving credit agreement on November 4, 2026, replacing its October 7, 2024 agreement.
• The revolver matures November 4, 2031, with commitments eligible to increase by up to $800 million, subject to conditions.
• FinCo separately secured a delayed draw term loan facility of up to $500 million, with J.P. Morgan SE as administrative agent.
• The term loan requires completion of the Xodus Medical acquisition before funding; maturity falls five years after the acquisition closes.
• Both facilities carry floating interest rates with margins determined by the company's debt rating.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Steris plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-447617), on November 04, 2026, and is solely responsible for the information contained therein.